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ABSTRACT
Between August 1989 and November 2003, 33 patients at our center with acquired aplastic anemia underwent bone
marrow transplantation (BMT) from HLA-identical sibling donors with cyclophosphamide and in vivo anti-CD52
monoclonal antibodies (MoAb) for conditioning. The median age at BMT was 17 years (range, 4-46 years). Before
BMT, 58% were heavily transfused (>50 transfusions), and 42% had previously experienced treatment failure with
antithymocyte globulin–based immunosuppressive therapy. Unmanipulated bone marrow was used as the source of
stem cells in all patients except 1. Graft-versus-host disease (GVHD) prophylaxis was with cyclosporine alone in 19
(58%) patients; 14 received anti-CD52 MoAb in addition to cyclosporine. The conditioning regimen was well
tolerated without significant acute toxicity. Graft failure was seen in 8 patients (primary, n  4; secondary, n  4).
Of those whose grafts failed, 4 survived long-term (complete autologous recovery, n  2; rescue with previously
stored marrow, n  1; second allograft, n  1). The cumulative incidence of graft failure and grade II to IV acute
and chronic GVHD was 24%, 14%, and 4%, respectively. None developed extensive chronic GVHD. With a median
follow-up of 59 months, the 5-year survival was 81% (95% confidence interval, 68%-96%). No unexpected early or
late infectious or noninfectious complications were observed. We conclude that the conditioning regimen contain-
ing cyclophosphamide and anti-CD52 MoAb is well tolerated and effective for acquired aplastic anemia with
HLA-matched sibling donors. The favorable effect on the incidence and severity of GVHD is noteworthy in this
study and warrants further investigation.
© 2004 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Bone marrow transplantation (BMT) from an
LA-identical sibling donor is the treatment of
hoice for acquired severe aplastic anemia (SAA)
1-4]. Two critical barriers to improved outcomes in
plastic anemia (AA) are graft failure and graft- c
B&MTersus-host disease (GVHD), which result in signif-
cant morbidity and mortality [5,6]. Antithymocyte
lobulin (ATG) was introduced in transplant pro-
ocols for AA in the late 1980s for patients receiving
second BMT for graft rejection [7]. Since then,
ncouraging results have been reported with the
ombination of ATG and cyclophosphamide (CY)
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8or initial transplantation: long-term survival
eaches close to 90% [8-10].
At St. George’s Hospital, we began to investigate
he role of anti-CD52 monoclonal antibodies (MoAb)
n the transplant protocols for AA in 1989. The CD52
ntigen is expressed widely on virtually all lympho-
ytes, including T and B cells, natural killer cells,
endritic cells, eosinophils, and macrophages, but it is
bsent from erythrocytes, platelets, and bone marrow
BM) progenitors [11,12]. The anti-CD52 MoAb
ampath-1G (rat immunoglobulin G2b) and Cam-
ath-1H (humanized immunoglobulin G1) effectively
eplete lymphocytes and antigen-presenting cells and
educe the risk of both acute and chronic GVHD, as
ell as graft rejection, in stem cell transplantation
13]. However, this approach may compromise the
raft-versus-leukemia effect, so an increased risk of
elapse is possible in malignant disorders [14]. In con-
rast, graft-versus-leukemia is not an issue in nonma-
ignant disorders of BM, and an agent capable of
acilitating engraftment and reducing GVHD is of
articular interest.
In a pilot study, we previously reported on the effects
f in vivo Campath-1G in combination with CY on
VHD and engraftment in marrow transplantation for
A [15]. In this retrospective study, we report the long-
erm outcome in 33 patients with acquired AA who
nderwent transplantation at St. George’s Hospital, and
e evaluate the patient-, disease-, and transplant-related
actors for outcomes. This is the ﬁrst study to evaluate
he long-term outcome of acquired AA patients under-
oing transplantation with CY and in vivo anti-CD52
oAb.
ATERIALS AND METHODS
atients
This study includes 33 consecutive patients who
eceived transplants from HLA-identical sibling do-
ors at our center from August 1989 to November
003 with CY and anti-CD52 MoAb. Eighteen pa-
able 1. Anti-CD52 Monoclonal Antibody Schedules and GVHD Prop
Time (Relative to Transplantation) No. of Patients
Days 8 to 0 10
Days 8 to 1 4
Days 6 to 0 2*
Days 7 to 4 2
Days 7 to 1 2
Days 8 to 5 1
Days 9 to 4 1
Days 9 to 6 3
Days 7 to 3 1
Days 9 to 5 7
oAb indicates monoclonal antibody; GVHD, graft-versus-host d
One patient received Campath for only 2 days because of infusionients with acquired AA reported previously in our t
68ilot study are included in this report [15]. Patient
ummaries were entered into a database that was up-
ated regularly for various outcomes and checked
gainst the original case notes. Each patient or guard-
an gave informed consent for the transplantation.
he study was approved by the local research and
thics committee.
All patients fulﬁlled the deﬁnition of SAA [16]
xcept for 1 (neutrophils 1.2  109/L), who had mul-
iple episodes of severe bleeding and whose disease
ehaved phenotypically like SAA. The relevant blood
lms and marrow histology were reviewed before
MT in all patients. All patients were screened and
ere negative for Fanconi anemia according to chro-
osomal breakage studies with diepoxybutane. The
edian time from diagnosis to BMT was 3 months
range, 1-80 months). The median follow-up of sur-
ivors was 59 months (range, 6-150 months).
ransplantation Procedure
All patients received high-dose CY 50 mg/kg  4
day 5 to 2), with mesna for the prevention of
emorrhagic cystitis. During the study period, various
chedules of anti-CD52 MoAb were used (Table 1).
he total dose of anti-CD52 MoAb was 0.75 to
mg/kg body weight. The total dose is expressed as
illigrams per kilogram body weight because the
tudy included both adults and children. Before 1999,
at-derived Campath was used (Campath-1G). We
witched to Campath-1H (alemtuzumab) when it be-
ame available in 1999.
Unmanipulated BM was used as the source of stem
ells in all patients except 1, who received peripheral
lood stem cells (PBSCs) from a donor mobilized with
ranulocyte colony-stimulating factor. Cyclosporine
CSA) alone was used for GVHD prophylaxis in 19
58%) patients. Fourteen patients received anti-CD52
oAb over 4 to 5 days (total dose, 0.5 mg/kg body
eight) in addition to CSA (Table 1). CSA was started
ntravenously at 5 mg/kg/d from day 1 and was then
iven orally when gastrointestinal function was rees-
e of Anti-CD52 MoAb GVHD Prophylaxis
Campath-1G CSA, Campath-1G (days 1 to 5)
Campath-1G CSA, Campath-1G (days 2 to 5)
Campath-1G CSA
Campath-1G CSA
Campath-1G CSA
Campath-1G CSA
Campath-1G CSA
Campath-1G CSA
Campath-1H CSA
Campath-1H CSA
CSA, cyclosporine.
d toxicity.hylaxis
Typ
isease;ablished: trough levels were maintained between 200
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Cyclophosphamide and Anti-CD52 MoAb for Acquired AA
Bnd 250 g/L. CSA was continued up to 12 months
fter BMT; tapering began at 9 months unless there
as evidence of mixed chimerism, in which case it was
ontinued longer.
upportive Therapy
All patients were nursed in single laminar airﬂow
solation rooms until the absolute neutrophil count
ANC) was 0.5  109/L for 3 consecutive days. Leu-
odepleted blood products were used throughout, and
ytomegalovirus (CMV)–seronegative blood products
ere given when both recipient and donor were CMV
egative on serology. CMV reactivation was monitored
y CMVbuffy coat on a weekly basis up to 3months and
s clinically indicated. Since 1992, patients who experi-
nced reactivation of CMV infection were treated with
anciclovir or foscarnet.
himerism Studies
From 1989 to 2001, chimeric studies were per-
ormed in Dublin by using microsatellite markers to
creen donor and recipient pairs for informative poly-
orphisms, as previously described [17]. From 2002,
himerism testing was performed sequentially on pe-
ipheral blood by using Y chromosome–speciﬁc comple-
entary DNA probes in patients with a donor of the
pposite sex or probes speciﬁc for polymorphic DNA
equences (short tandem repeats). The chimerism stud-
es were performed at approximately 1 month, 3 months,
nd 1 year and as clinically indicated. Mixed chimerism
as deﬁned as previously described by
cCann et al. [18].
efinitions and Evaluation of Response
At the time of BMT, performance status was
eﬁned according to the Karnofsky scale for pa-
ients 16 years and the Lansky scale for those 16
ears. A performance status of 80 was deﬁned as
ood and 80 as poor. Platelet refractoriness was
eﬁned as a platelet increment 10  109/L to
andom donor platelets 1 hour after infusion of
latelets in the absence of fever or bleeding. Infor-
ation on key therapies before BMT and their
esponses was available for all patients. A key therapy
as deﬁned as ATG-based or antilymphocyte glob-
lin–based therapy, CSA, or oxymetholone. Where
SA was given as part of an ATG/antilymphocyte
lobulin protocol, it was considered as 1 key ther-
py. Granulocyte colony-stimulating factor or cor-
icosteroids were not considered as key therapies.
Myeloid and platelet engraftment were deﬁned
s the ﬁrst of 3 consecutive days with an ANC 0.5
109/L and unsupported platelets 50  109/L,
espectively. Patients were evaluable for engraft-
ent if they survived at least 21 days after trans-
lantation. Patients who did not have a neutrophil t
B&MTount 0.5  109/L for 3 consecutive days were
onsidered as having primary graft failure, and
able 2. Baseline and Transplant Characteristics of the Study Patients
Characteristic Data
o. patients 33
edian age at diagnosis, y (range) 16 (4-45)
edian age at BMT, y (range) 17 (4-46)
roportion of males (%) 15 (45%)
tiology of AA
Idiopathic 25 (76%)
Drug induced 1 (3%)
Hepatitis 5 (15%)
PNH 2 (6%)
o of key therapies failed before BMT
None 16 (49%)
1 11 (33%)
2 3 (9%)
>3 3 (9%)
ailed ALG/ATG  CSA before BMT
Yes 14 (42%)
No 19 (58%)
o. transfusions before BMT
<50 14 (42%)
>50 19 (58%)
efractory to random platelet transfusion
Yes 4 (12%)
No 29 (88%)
S before BMT
Good 24 (73%)
Poor 9 (27%)
ctive infection 1 wk before BMT
Yes 9 (27%)
No 24 (73%)
ime from diagnosis to BMT
<12 mo 26 (79%)
>12 mo 7 (21%)
ource of stem cells
BM 32 (97%)
PB 1 (3%)
emale donor
No 22 (67%)
Yes 11 (33%)
BO (D/R) blood group incompatibility
No 24 (73%)
Yes (minor and major) 9 (27%)
ecipient seropositive for CMV
No 14 (42%)
Yes 19 (58%)
raft TNC infused (108/kg) (n  30)
<3 8 (27%)
>3 22 (73%)
eriod of BMT
1989-1995 19 (58%)
1996-2003 14 (42%)
VHD prophylaxis
CSA alone 19 (58%)
CSA plus anti-CD52 MoAb 14 (42%)
MT indicates bone marrow transplantation; AA, aplastic anemia;
PNH, paroxysmal nocturnal hemoglobinuria; ATG, antithymo-
cyte globulin; ALG, antilymphocyte globulin; CSA, cyclospor-
ine; PS, performance status; PB, peripheral blood; BM, bone
marrow; MoAb, monoclonal antibody; TNC, total nucleated
count; CMV, cytomegalovirus; GVHD, graft-versus-host dis-
ease.hose who achieved initial engraftment but subse-
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8uently had severely hypocellular marrow or ANC
0.5  109/L were deﬁned as having secondary
raft failure.
Patients with sustained donor engraftment who
urvived more than 14 and 100 days after transplan-
ation were evaluable for the occurrence of acute
nd chronic GVHD, respectively. The severity of
cute and chronic GVHD was scored according to
he previously deﬁned criteria [19,20]. The devel-
pment of GVHD was monitored and scored reg-
larly, and for study evaluation, the severest grade
f GVHD was taken. Overall survival was the time
rom BMT to death or last follow-up.
tatistical Analysis
Data were updated as of June 7, 2004. The main
utcomes of interest were engraftment, acute and
hronic GVHD, infectious complications, treatment-re-
ated mortality, survival, and long-term complications.
esults were reported as proportion and 95% conﬁ-
ence intervals (CIs). The P values were determined
ccording to the 2-sided test. The Kaplan-Meier method
as used to estimate survival [21]. The cumulative inci-
ences of graft failure and acute and chronic GVHD
ere estimated with the Cmprsk package in R software.
he risk of dying from other causes was treated as the
ompeting event [22]. For univariate analysis, Fisher i
70xact tests or log-rank tests were used to examine the
ssociation between graft failure or survival and patient-,
isease-, and transplant-related characteristics, as appro-
riate. All analyses were performed with SAS 8.01 (SAS
nstitute, Cary, NC).
ESULTS
The baseline and transplant characteristics of the
tudy cohort are shown in Table 2. Of particular note,
2% had experienced failure with previous ATG-based
mmunosuppressive therapy, and 58% patients were
eavily transfused (50 transfusions) before BMT.
ngraftment
Myeloid engraftment occurred in 29 patients at a
edian of 16 days (range, 10-37 days). Of these 29
atients, 27 also achieved platelet counts50 109/L at
median of 28 days (range, 14-73 days). Four patients
ad primary graft failure, and 4 developed secondary
raft failure at days 20, 40, 45, and 53 after
MT. Of all the graft failures (n  8), 2 patients had
pontaneous complete autologous recovery, 1 patient
ecovered after rescue with stored autologous BM, and 1
atient received a second allograft from the same donor
nd recovered. The other 4 patients died from various
igure 1. Cumulative incidence of graft failure (death not related to
raft failure was considered a competing risk). Cumulative inci-
ence of grade II to IV acute GVHD (death not related to GVHD
as considered a competing risk). Cumulative incidence of chronic
VHD (death not related to GVHD was considered a competing
isk).F
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Cyclophosphamide and Anti-CD52 MoAb for Acquired AA
Braft failure was 24% (95%CI, 13%-45%; Figure 1a). In
univariate analysis, no factors were predictive of graft
able 3. Univariate Analysis of Factors Predicting Graft Failure
Covariate
Graft
Failure/Total
No.
Patients
P Value
(Fisher’s
Exact
Test)
o. patients 8/33 (24%) —
ge (y)
<20 4/18 (22%) 1.00
>20 4/15 (27%)
ex
Male 2/15 (13%) .24
Female 6/18 (33%)
tiology of AA
Idiopathic 6/25 (24%) 1.00
Other 2/8 (25%)
o. key therapies failed before BMT
None 4/16 (25%) 1.00
>1 (range 1-4) 4/17 (24%)
ailed ALG/ATG  CSA before
BMT
No 5/19 (26%) 1.00
Yes 3/14 (21%)
o. of transfusions before BMT
<50 2/14 (14%) .41
>50 6/19 (32%)
efractory to platelet transfusion
Yes 2/4 (50%) .24
No 6/29 (21%)
S before BMT
Good 6/24 (25%) 1.00
Poor 2/9 (22%)
ctive infection before BMT
Yes 2/9 (22%) 1.00
No 6/24 (25%)
ime from diagnosis to BMT
<12 mo 5/26 (19%) .32
>12 mo 3/7 (18%)
emale donor
Yes 2/11 (18%) .68
No 6/22 (27%)
BO (D/R) blood group
incompatibility
No 4/24 (17%) .17
Yes (major  minor) 4/9 (44%)
ecipient CMV seropositive
Yes 3/14 (21%) 1.00
No 5/19 (26%)
raft TNC (108/kg) (n  30)
<3 2/8 (25%) 1.00
>3 5/22 (23%)
eriod of BMT
1989-1995 5/19 (26%) 1.00
1996-2003 3/14 (21%)
VHD prophylaxis
CSA alone 3/19 (16%) .24
CSA plus anti-CD52 MoAb 5/14 (36%)
MT indicates bone marrow transplantation; AA, aplastic anemia;
ATG, antithymocyte globulin; ALG, antilymphocyte globulin;
CSA, cyclosporine; PS, performance status; MoAb, monoclonal
antibody; TNC, total nucleated count; CMV, cytomegalovirus;
GVHD, graft-versus-host disease.ailure (Table 3).
B&MTraft-versus-Host Disease
Of the 29 patients evaluable for acute GVHD,
one was seen in 23 (79%). Six developed acute
VHD (grade I, n  2; grade II, n  3; grade IV,
 1; Table 4). Grade II acute GVHD resolved with
ral steroids within 5 to 7 days in all patients. The 1
atient with grade IV GVHD developed CMV pneu-
onia and died. This was before the availability of
anciclovir. Of the 25 patients evaluable for chronic
VHD, only 1 patient developed limited GVHD. Of
he patients who received GVHD prophylaxis with
SA and anti-CD52 MoAb, none developed acute or
hronic GVHD. The cumulative incidence of grade II
o IV acute and chronic GVHD was 14% (95% CI,
%-35%) and 4% (95% CI, 1%-29%), respectively
Figure 1b and 1c).
nfectious Complications
Infectious complications during the ﬁrst 100 days
nd after 100 days are shown in Table 5. Nineteen
ecipients were serologically positive for CMV before
MT. CMV reactivation was seen in 5 within the ﬁrst
00 days (CMV infection, n  2; CMV disease, n 
). CMV disease affected the lungs (n  2) or gastro-
ntestinal tract (n  1). No cases of late CMV reacti-
ation were seen. There was no difference in infec-
ious complications in the patients who received
VHD prophylaxis with CSA alone compared with
able 4. Noninfectious Complications after BMT for Acquired AA
Timing Complication
No.
Evaluable n (%)
100 after
BMT
Graft failure
Primary 33 4 (12%)
Secondary 29 4 (14%)
Hemorrhagic cystitis 33 2 (6%)
Acute GVHD 29
None 23 (79%)
Grade I 2 (7%)
Grade II 3 (10%)
Grade III 0
Grade IV 1 (3%)
VOD 33 0
Idiopathic pneumonia
syndrome 33 0
100 d after
BMT
Graft failure 25 0
Chronic GVHD 25
None 24 (96%)
Limited 1 (4%)
Extensive 0
Secondary
malignancy 28
Yes 1 (4%)
No 27 (96%)
Avascular necrosis 28 1 (4%)
Autoimmune
cytopenias 28 1 (4%)
MT indicates bone marrow transplantation; GVHD, graft-versus-
host disease; VOD, veno-occlusive disease; AA, aplestic anemia.
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8hose who received anti-CD52 MoAb in addition to
SA (data not shown).
oxicity
Intravenous infusions of anti-CD52MoAbwere well
olerated in all but 1 patient, in whom the drug was
iscontinued after 2 doses because of uncontrollable fe-
ers, rigors, and tachycardia, despite multiple doses of
ydrocortisone, antihistamine, and pethidine. No ana-
hylactic reactions, rashes, myalgias, or arthralgias were
bserved. Despite routine mesna in all patients, 2 pa-
ients developed hemorrhagic cystitis in the ﬁrst 2 weeks
f conditioning therapy. No infectious etiology for hem-
rrhagic cystitis was found in these patients, and this was
ttributed to CY. There were no cases of severe mucosi-
is, veno-occlusive disease, or idiopathic pneumonia syn-
rome. None of the patients required parenteral nutri-
ion. The early and late noninfectious complications are
ummarized in Table 4.
auses of Death
Six patients died from complications related to
ransplantation at a median of 248 days (range, 47-
14 days). The main causes of death were infectious
omplications after graft failure (n  4), GVHD and
MV pneumonia (n  1), and autoimmune cytope-
ias with cerebral aspergillosis (as previously reported
23]; n  1).
urvival
The 5-year survival for the study cohort was 81%
95% CI, 68%-96%; Figure 2a). In a univariate analysis,
nferior survival was associated with a high number of
ransfusions (50) before BMT, refractoriness to plate-
et transfusion before BMT, active infection before
MT, and ABO blood group incompatibility between
able 5. Infectious Complications after BMT for Acquired SAA
Timing Complication
No.
Evaluable n (%)
100 d
after
BMT
Bacterial (culture positive) 33 15 (45%)
Fungal (probable/proven) 33 3 (9%)
CMV (seropositive
recipients, n  19)
33
CMV infection 3
CMV disease 2
Adenovirus 33 0
Herpes zoster 33 1
100 d
after
BMT
Bacterial 28 2 (7%)
Viral 28 2 (7%)
HSV 1 (4%)
Herpes zoster 1 (4%)
Fungal 28 1 (4%)
Late CMV reactivation 28 0
MV indicates cytomegalovirus; HSV, herpes simplex virus; BMT,
bone marrow transplantation; SAA, severe aplastic anemia.he donor and recipient (Table 6). There was no effect [
72n survival of age (continuous and categorical variable),
revious use of ATG-containing immunosuppressive
herapy, and GVHD prophylaxis. There was an im-
rovement in survival in the transplantations performed
fter 1995 (93% versus 74%), although this was not
tatistically signiﬁcant (Figure 2b).
ong-Term Complications
One patient, as previously reported, developed
pstein-Barr virus–associated B-cell lymphoprolifera-
ive disease 4.6 months after BMT [24]. The tumor
ompletely regressed after withdrawal of CSA and
onor lymphocyte infusion. No other cases of second-
ry malignancy were seen. One patient, as previously
eported, developed autoimmune cytopenias 10
onths after BMT and died of cerebral aspergillosis
23]. One patient developed avascular necrosis (AVN)
f the left hip 8 years after BMT.
himerism Evaluations
Of the 27 survivors, serial chimerism data were
vailable for 18 (67%) patients. The evaluations
igure 2. Kaplan-Meier plots of survival among the 33 patients with
cquired AA who received transplants from HLA-identical sibling
onors with CY and anti-CD52 MoAb. The overall survival was 81%
95% CI, 68%-96%). The dotted lines on the survival curve represent
onﬁdence intervals. There was a nonsigniﬁcant trend toward better
urvival in patients who underwent transplantation after 1995 (93%
80%-100%] versus 74% [56%-96%]; P  .19).
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Cyclophosphamide and Anti-CD52 MoAb for Acquired AA
Bhowed 100% donor cells in 13 (72%) patients, stable
ixed chimerism with 85% donor cells in 3 (17%)
atients, and autologous recovery in 2 (11%) patients.
erformance Status and Fertility
The performance status of all survivors (n 27) was
00%, except for 1 patient, who developed AVN. All the
urvivors were transfusion independent at last follow-up.
able 6. Univariate Analysis of Factors Predicting Survival
Covariate Dead/Total N
o. patients 6/33 (1
ge (y)
<20 3/18 (1
>20 3/15 (2
ex
Male 3/15 (2
Female 3/18 (1
tiology of AA
Idiopathic 4/25 (1
Others 2/8 (1
o. key therapies failed before BMT
None 2/16 (1
>1 (range, 1-4) 4/17 (2
ailed ALG/ATG  CSA before BMT
No 2/19 (1
Yes 4/14 (2
o. transfusions before BMT
<50 0/14 (0
>50 6/19 (3
efractory to platelet transfusion
Yes 3/4 (7
No 3/29 (1
erformance status
Good 3/24 (1
Poor 3/9 (3
ctive infection before BMT
Yes 4/9 (4
No 2/24 (8
ime from diagnosis to BMT
<12 mo 5/26 (1
>12 mo 1/7 (1
emale donor
No 4/22 (1
Yes 2/11 (1
BO (D/R) blood group incompatibility
No 2/24 (8
Yes (minor and major) 4/9 (4
ecipient CMV seropositive
Yes 4/19 (2
No 2/14 (1
raft TNC (108/kg) (n  30)
<3 2/8 (2
>3 4/22 (1
eriod of BMT
1989-1995 5/19 (2
1996-2003 1/14 (7
VHD prophylaxis
CSA alone 3/19 (1
CSA plus anti-CD52 MoAb 3/14 (2
MT indicates bone marrow transplantation; ATG, antithymocyte
nucleated count; OS, overall survival; CI, conﬁdence interval;
disease.f the surviving 19 patients (70%) aged 18 years, c
B&MTnformation on conception was available for 16 (11
omen and 5 men). Of these, 4 women and partners of
men had conceived. All the babies born were healthy
nd without any congenital malformations.
ISCUSSION
Currently CY with ATG is considered standard
ients % 5-y OS (95% CI)
P Value
(Log-Rank Test)
81 (68-96) —
83 (67-100) .98
80 (62-100)
79 (60-100) .90
83 (67-100)
83 (69-100) .57
75 (50-100)
88 (73-100) .39
74 (55-100)
89 (76-100) .18
69 (47-100)
100 .03
68 (50-92)
25 (5-100) .0002
89 (78-100)
87 (74-100) .12
67 (42-100)
53 (28-100) .02
92 (82-100)
80 (65-98) .76
86 (64-100)
78 (55-100) .95
82 (67-100)
92 (82-100) .02
53 (28-100)
79 (63-100) .67
83 (63-100)
75 (50-100) .33
80 (62-100)
74 (56-96) .22
93 (80-100)
84 (69-100) .75
78 (58-100)
lin; CSA, cyclosporine; MoAb, monoclonal antibody; TNC, total
lastic anemia; CMV, cytomegalovirus; GVHD, graft-versus-hosto. Pat
8%)
7%)
0%)
0%)
7%)
6%)
1%)
4%)
4%)
1%)
9%)
%)
2%)
5%)
0%)
3%)
3%)
4%)
%)
9%)
4%)
8%)
8%)
%)
4%)
1%)
4%)
5%)
8%)
6%)
%)
6%)
1%)
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8A with HLA-identical sibling donors. Long-term
urvival with this regimen has been reported in the
ange of 85% to 90% [2,8-10]. The 5-year survival in
his study (81%; 95% CI, 68%-96%) seems compa-
able to that in studies using CY and ATG condition-
ng. In line with the reported trend [3,25,26], our
tudy showed that the outcome of marrow transplan-
ation for acquired AA continues to improve with
ime; the 5-year survival of patients who underwent
ransplantation after 1995 was 93% (95% CI, 80%-
00%). Possible causes of improved survival in the
atients who have undergone transplantation in recent
ears are better transfusion practices, newer antimi-
robial drugs, and better support facilities. In a uni-
ariate analysis, a high number of transfusions (50)
efore BMT, platelet refractoriness before BMT, ac-
ive infection, and ABO incompatibility were signiﬁ-
ant adverse factors for survival. Unlike some previous
tudies, we did not note an adverse effect on survival of
ncreasing age, previously failed immunosuppressive
herapy, or time from diagnosis to BMT 12 months
10,26,27]. Because of the limited sample size, it is not
ossible to perform a multivariate analysis to under-
tand the independent prognostic signiﬁcance of these
actors. Nevertheless, this is the largest experience of
arrow transplantations for acquired AA by using CY
nd in vivo anti-CD52 MoAb.
The main advantage of CY and anti-CD52 MoAb
ompared with CY and ATG seems to be in terms of
he incidence and severity of GVHD. The cumulative
ncidence of grade II to IV acute and chronic GVHD
ith CY and ATG has been reported in the range of
0% to 40% [10,26]. In comparison, the cumulative
ncidence of grade II to IV acute (14%) and chronic
4%) GVHD was favorable in this study. Moreover,
one of the patients developed extensive chronic
VHD. Previous studies showed that chronic GVHD
as the main factor for late complications in the ac-
uired AA patients, resulting in worse survival [26,28].
oreover, the adverse effect of chronic GVHD on
uality of life, performance status, pulmonary func-
ion, and psychological symptoms is well known
28,29].
The incidence of graft failure with CY and ATG
as been reported as 5% to 10% [2,9,10,30]. In our
tudy, the cumulative incidence of graft failure (24%)
eemed higher, because 8 patients had graft failure
primary, n  4; secondary, n  4). A low marrow cell
ose (3 108/kg) and a high number of transfusions
efore BMT have been identiﬁed in previous studies
s factors predictive of graft failure [5,6,31,32]. A
igher incidence of graft failure in our study may be
ue to large proportion of patients (58%) being
eavily transfused. Another contributory factor may
e the combined GVHD prophylaxis with CSA and
nti-CD52 MoAb. This approach probably resulted in
epletion of donor T cells, which are important for o
74ngraftment. The half-life of licensed humanized anti-
D52 MoAb (alemtuzumab or Campath-1H) is sig-
iﬁcantly longer (2-3 weeks), compared with 13 hours
or MoAb derived from rat (Campath-1G) [33]. In
iew of the observations from our patients and the
onger half-life of alemtuzumab, we currently use CSA
lone as GVHD prophylaxis. Although the number of
atients treated with the latest schedule of alemtu-
umab (days 9 to 5) is small at present, none has
eveloped graft failure. On the basis of these ﬁndings,
his is our protocol for future prospective study.
The preferred source of stem cells in our patients
as BM (97%). The use of PBSCs as an alternative
tem cell source to BM in allotransplantation is in-
reasing. A collaborative retrospective study from the
uropean Blood and Marrow Transplant Group and
he International Bone Marrow Transplant Registry
ompared the outcome of allogeneic BM and PBSC
ransplantation for AA [34]. This study showed that
he 2-year probabilities of survival after PBSC and
M transplantation were 67% and 80%, respectively
P .05). The difference in survival was mainly due to
he adverse effect of increased chronic GVHD with
BSC compared with BM (29% versus 16%; P .01).
lthough there was no difference in the rates of graft
ailure in the 2 groups, both myeloid and platelet
ngraftment were signiﬁcantly faster with PBSC. It
an be hypothesized that the use of anti-CD52 MoAb
n the conditioning may overcome the problem of
hronic GVHD with PBSC grafts. This remains spec-
lative and may be a future study question.
One concern with the use of anti-CD52 MoAb in
MT is the possibility of delayed immune reconstitu-
ion, resulting in an increased risk of infectious viral
omplications such as CMV, adenovirus, and respira-
ory viruses [35-37]. In this study, the incidence of
MV reactivation was 26% in ﬁrst 100 days in recip-
ents serologically positive for CMV. No cases of late
MV reactivation were observed. The incidence of
acterial, fungal, and other viral complications does
ot seem to be higher than expected in these patients.
o other unexpected acute noninfectious toxic com-
lications were observed with this regimen. The lower
ncidence of toxic complications may also be related to
act that we did not use methotrexate for GVHD
rophylaxis. Previous studies demonstrated that the
ncidence of severe pulmonary complications and mu-
ositis is higher with combined prophylaxis with CSA
nd methotrexate [38].
The risk of secondary cancers in patients with SAA
ndergoing BMT has been reported in the range of
0% to 20% [26,28,39-41]. Apart from 1 patient who
eveloped Epstein-Barr virus–induced lymphoprolif-
rative disorder, no other cases of secondary malig-
ancy were seen on long-term follow-up. In compar-
son to other studies, the incidence of AVN was low in
ur study [26,28,42]. Old age and use of steroids to
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Breat GVHD are considered risk factors for AVN.
he incidence of long-term bacterial, viral, and fungal
omplications seems to be low compared with other
tudies [26,28,43]. The lower incidence of these com-
lications is probably related to the decreased inci-
ence and severity of GVHD resulting in minimal
teroid use. Our study validates the previously re-
orted ﬁndings on maintaining gonadal function with
igh-dose CY–containing conditioning, because 37%
atients older than age 18 either became pregnant or
athered a child [28,44]. The information on how
any of them were attempting to have children was
ot available.
In summary, we have shown that conditioning
onsisting of CY and anti-CD52 MoAb is well toler-
ted and effective for marrow transplantation from
LA-identical sibling donors for acquired AA. The
ncidence of graft failure seems moderately high but
ay decrease with optimization of the administration
chedule for anti-CD52 MoAb. The favorable effect
n the incidence and severity of GVHD is noteworthy
n this study and warrants further investigation.
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